Crucell to Receive $5 Million From Aeras for Development of TB Vaccine
Posted on: Friday, 21 December 2007, 12:00 CST
Crucell has reported that it will receive up to $5 million from Aeras Global TB Vaccine Foundation to support the advanced development of its AdVac-and PER.C6-based tuberculosis vaccine.
Aeras and Crucell began jointly developing this vaccine candidate, called AERAS-402, in 2004 using Crucell's AdVac vaccine technology and PER.C6 manufacturing technology. A Phase I clinical trial launched in October 2006 in the US, indicates that the vaccine candidate is safe in healthy adults in the US. A second study in progress in healthy adults in South Africa appears to be showing safety, tolerability and immunogenicity of AERAS-402.
Crucell and Aeras have also announced the launch of a new Phase I BCG-Ad35 prime boost clinical trial of the unique AdVac-based tuberculosis vaccine. The trial will be conducted in St. Louis, Missouri, US at the Saint Louis University Center for Vaccine Development.
The main parameters under examination in the study will be the immunogenicity and safety of BCG prime followed by two AERAS-402 boost doses administered at three to six month intervals after BCG in healthy adults. The trial will be conducted as double-blind, randomized, placebo-controlled study in 32 healthy adult volunteers.
Source: Datamonitor
Related Articles
- Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
- AVANT's Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study
- Iomai's Self Applied Diarrhea Vaccine Found Effective in Phase II Study
- Study: Adult Stem Cells for Heart Repair?
- Novavax Improved HIV Vaccine to Enter Human Trials
- Sanofi Pasteur PER.C6(R)-Based Seasonal Influenza Vaccine Enters First Clinical Trial
- Protherics Acquires Novel Vaccine Adjuvant And Prepares For Phase 2 Study Of Its Angiotensin Vaccine
- Cancer Vaccines Facing Difficult Clinical Trial Challenges; Greystone Associates Cites Enrollment, Endpoint, and Protocol Issues
- Diamyd Medical Appoints Protein Sciences 'USA' for Production of Its Lead Therapeutic Diabetes Vaccine for Phase III-Trials and to Submit an IND to the FDA
- Phase III Study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19
 |
 |
User Comments (0)
RSS Feeds